Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.

@article{Minckwitz2011IntegratingBE,
  title={Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.},
  author={Gunter von Minckwitz and Holger Eidtmann and Sibylle Loibl and J U Blohmer and Sandra Da Costa and Peter A. Fasching and Rolf Kreienberg and Joern Hilfrich and Bernd Gerber and Claus Hanusch and Tanja N. Fehm and Dirk Strumberg and Christine Solbach and Valentina Nekljudova and Michael Untch},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 2},
  pages={301-6}
}
BACKGROUND Safety data for combining bevacizumab, everolimus, or lapatinib with anthracycline- and taxane-based neoadjuvant chemotherapy for breast cancer are limited. PATIENTS AND METHODS The neoadjuvant GeparQuinto trial investigates the addition of (i) bevacizumab to four cycles epirubicin/cyclophosphamide (EC) followed by four cycles docetaxel (Taxotere) in patients with human epithelial growth factor receptor (HER)2-negative tumors, (ii) everolimus to weekly paclitaxel in patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Lapatax: a phase I study of neoadjuvant lapatinib combined with docetaxel in Her2/neu overexpressing breast cancer (BC). EORTC protocol 10054

  • H Bonnefoi, K Zaman, M Nobahar
  • San Antonio Breast Cancer Symposium, San Antonio,
  • 2008
Highly Influential
7 Excerpts

A Phase Ib Trial of RADD001, an MTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer

  • IA Mayer, HA Burris, JC Bendell
  • San Antonio Breast Cancer Symposium, San Antonio,
  • 2009
1 Excerpt

Safety and activity report of a randomized phase II trial of preoperative anthracycline-based chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: CHERLOB trial

  • V Guarneri, A Frassoldati, A Bottini
  • San Antonio Breast Cancer Symposium, San Antonio,
  • 2009
1 Excerpt

Surgical complications and the use of neoadjuvant bevacizumab

  • M Golshan, J Garber, R Gelman
  • San Antonio Breast Cancer Symposium, San Antonio,
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…